Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANKU-Esophagus02: BL-B01D1 + tislelizumab ± fluorouracil versus platinum-based chemotherapy + tislelizumab in first-line advanced esophageal squamous cell carcinoma
CTR20261548Phase 3Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of izalontamab brengitecan in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Biokin Pharmaceutical. Started Jun 2026; status: active.
02
Drugs
izalontamab brengitecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on CTR20261548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261548.